This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Modelling
A decision tree model was developed to analyse the cost-effectiveness of the five strategies considered in this study. The model had 1-year cycles over a 5-year period (2000 -2005) . The model was adjusted for annual compliance rates, as well as expected mortality and excess mortality incurred by certain fractures. In addition to the hip and spine fractures, non-hip and non-vertebral fractures were also included in the model (ankle, non-ankle tibial-fibular, patella, distal femur, pelvic, wrist, non-wrist radial-ulnar, distal humeral shaft, and proximal humeral).
Outcomes assessed in the review
The outcomes estimated were the age-group prevalence of osteoporosis, the fracture incidence rates, the fracture reduction efficacy of each treatment, and the compliance rates.
Study designs and other criteria for inclusion in the review
Randomised controlled trials (RCTs) were used to assess the fracture reduction efficacy of each therapy. The age-group prevalence of osteoporosis was based on the results of 204 consecutive central dual X-ray densitometer (DXA) examinations. The percentages obtained from these 204 studies were applied to the whole population. Other study designs were not reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
The validity of the primary studies does not appear to have been assessed.
Number of primary studies included
Twenty-one studies were included in the review.
Methods of combining primary studies
A narrative method was used to combine the primary studies.
Investigation of differences between primary studies
Results of the review
The prevalence of osteoporosis was 15% in women aged 65 to 69 years, 20% in women aged 70 to 74, 20.4% in women aged 75 to 79, 25.8% in women aged 80 to 84, and 62.5% in women aged 85 or older.
The cumulative 5-year hip fracture incidence rate ranged from 59.9 (age group 65 to 69) to 345.5 (age group 85 and older).
The cumulative 5-year non-hip, non-vertebral fracture incidence rate ranged from 385.2 (age group 80 to 84) to 549.1 (age group 70 to 74).
The cumulative 5-year vertebral fracture rate ranged from 53.8 (age group 65 to 69) to 130.9 (age group 80 to 84).
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The vertebral fracture reduction efficacy was 0.34 with calcitonin, 0.36 with raloxifene, 0.50 with bisphosphonates and 0.65 with PTH.
The hip fracture reduction efficacy was 0 with calcitonin and with raloxifene, and 0.50 with bisphosphonates.
The non-hip, non-vertebral fracture reduction efficacy was 0 with calcitonin and with raloxifene, 0.51 with bisphosphonates and 0.35 with PTH.
The annual compliance over a 5-year period was 0.676 with calcitonin (compliance rates for year 1 to 5: 0.80, 0.73, 0.68, 0.61, 0.56).
For years 1 to 3, the compliance rate with raloxifene was 0.80 for year 1, 0.71 for year 2 and 0.62 for year 3.
For years 1 to 3, the compliance rate with bisphosphonates was 0.80 for year 1, 0.60 for year 2 and 0.40 for year 3.
Methods used to derive estimates of effectiveness
The authors supplemented the data derived from the literature with some assumptions.
Estimates of effectiveness and key assumptions
It was assumed that the hip fracture reduction efficacy with PTH equated that of other peripheral fractures (i.e. 0.35).
Although PTH displayed a compliance rate of 79 to 83% in a randomised trial, the authors reduced this to 50% based on patients who would be medically ineligible for treatment. Since published compliance rates were not available for the 5-year span in the raloxifene and bisphosphonates strategies, the data for the last 2 years were estimated on the basis of the last 3 years. The estimated figures were 0.53 and 0.44 for raloxifene and 0.35 and 0.30 for bisphosphonates. Therefore, annual compliance over a 5-year period was 0.62 with raloxifene and 0.49 with bisphosphonates.
It was assumed that the fracture reduction efficacy of each agent continued throughout a 5-year period based on clinical trials of different durations (i.e. the raloxifene trial ended at 3 years, while PTH was administrated over an 18-month period).
Measure of benefits used in the economic analysis
The summary measures of health benefit used were the number of fractures prevented and the quality-adjusted lifeyears (QALYs) gained. These were estimated through the decision model, using data found in the literature. The health benefits were not discounted.
Direct costs
A discount rate of 3.5% was applied since the costs were incurred during 5 years. The direct costs included were those related to the screening process and the treatment of osteoporosis (DXA examinations, physician visits, comprehensive metabolic profiles, venous Doppler and prothrombin time studies, drugs and costs of fracture). The cost of fractures included physician visits, X-rays, materials, analgesic agents, physical therapy and hospitalisation. The unit costs and the quantities of resource used were presented separately for some items only. Some costs, such as the costs of fracture, were reported as macro categories. The costs were obtained from published data and several local sources, such as Medicare reimbursement rates; local pharmacy prices were used to calculate drug expenses. The price year was 2000.
Using a cost-effectiveness threshold of $100,000 or less per quality-adjusted life-year (QALY) gained, the universal screening of women aged 65 years or older for osteoporosis, and subsequent treatment with bisphosphonates, was a costeffective preventive intervention. This economic advantage was maintained in sub-sets of women who had a lower relative risk of future fracture.
CRD COMMENTARY -Selection of comparators
The authors did not explicitly justify their selection of the comparators. Nevertheless, it appears that most of the relevant treatments available for osteoporosis were taken into account, and only doses approved by the Food and Drug Administration (FDA) were used in the model. You should decide whether these are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The estimates of effectiveness were based on data derived from several published studies. However, no systematic review of the literature was undertaken and the differences between the primary studies were not taken into account in the analysis. The internal validity of the effectiveness estimations would have been higher had 'face to face' studies been available. Moreover, the authors acknowledged that several assumptions were used in the decision model. The impact of these assumptions was partly addressed in the sensitivity analyses, but they may still have had an influence on the overall conclusion of the analysis. Finally, the authors stated that the model was adjusted for expected as well as excess mortality incurred by certain fractures, but no mortality rates were reported in the article.
Validity of estimate of measure of benefit
The benefit measures used in the analysis were appropriate. The use of QALYs permits comparisons with the results of other studies. However, the health benefits were not discounted even though it would have been appropriate to do so since the time horizon of the model was 5 years.
Validity of estimate of costs
The analysis of the costs appears to have been performed from the perspective of the health care provider since the costs included were consistent with this viewpoint. The indirect costs were not included. The unit costs and the quantities of resource used were presented separately for some items only, thus limiting the possibility of replicating the study in other settings. The costs were derived from published sources. No sensitivity analyses were performed. The costs were appropriately discounted and the price year was reported, which will aid any future inflation exercises.
Other issues
The authors compared their results with those from other studies. The findings of this study contrast, in part, those of other economic evaluations. The authors stated that the differences might be explained by the fact that, in this study, compliance rates and non-hip, non-vertebral fracture rates were taken into account. The issue of generalisability was not explicitly addressed, but some sensitivity analyses were performed. The authors acknowledged several limitations to the study. The most important of these seems to have been that it was assumed that the fracture reduction efficacy of each agent continued throughout a 5-year period, based on clinical trials of shorter durations.
Implications of the study
The study results supported the recommendations from the United States Services Task Force and the National Osteoporosis Foundation for the screening of osteoporosis in all women aged 65 and older. The authors suggested that cost-analysis studies of osteoporosis should be structured on fracture reduction by FDA-approved drug doses and reasonable compliance rates, and should also include non-vertebral sites.
